The Schall Law Firm reminds investors of a class action lawsuit against Erasca, Inc. for alleged securities fraud. The lawsuit covers investors who purchased Erasca securities between January 14, 2025 and April 26, 2026, with a lead plaintiff deadline of August 10, 2026. The complaint alleges the company made false and misleading statements regarding preclinical data on ERAS-0015, including an improper comparison to Revolution Medicines, Inc. that risked patent violations and lacked basis for optimistic projections. When the market learned the truth, investors suffered damages.
Erasca IncSecurities fraud lawsuit alleging false statements about preclinical data and patent risks.
Revolution Medicines Inc